Synthesis and biological evaluation of all A-ring stereoisomers of 5,6-trans-2-methyl-1,25-dihydroxyvitamin D3 and their 20-epimers: possible binding modes of potent A-ring analogues to vitamin D receptor  by Fujishima, Toshie et al.
Research Paper
Synthesis and biological evaluation of all A-ring stereoisomers of
5,6-trans-2-methyl-1,25-dihydroxyvitamin D3 and their 20-epimers:
possible binding modes of potent A-ring analogues to
vitamin D receptor
Toshie Fujishima a, Katsuhiro Konno a, Kimie Nakagawa b, Maki Tanaka b,
Toshio Okano b, Masaaki Kurihara c, Naoki Miyata c, Hiroaki Takayama a; *
aFaculty of Pharmaceutical Sciences, Teikyo University, Sagamiko, Kanagawa 199-0195, Japan
bDepartment of Hygienic Sciences, Kobe Pharmaceutical University, Kobe 658-8558, Japan
cNational Institute of Health Sciences, Kamiyoga, Tokyo 158-8501, Japan
Received 3 May 2001; revisions requested 8 June 2000; revisions received 18 June 2001; accepted 21 June 2001
First published online 6 September 2001
Abstract
Background: The secosteroid 1K,25-dihydroxyvitamin D3
(1) has a wide variety of biological activities, which makes it a
promising therapeutic agent for the treatment of cancer,
psoriasis and osteoporosis. Insight into the structure^activity
relationships of the A-ring of 1 is still needed to assist the
development of more potent and selective analogues as candidate
chemotherapeutic agents, as well as to define the molecular mode
of action.
Results : All possible A-ring stereoisomers of 5,6-trans-2-methyl-
1,25-dihydroxyvitamin D3 (6a^h) and their 20-epimers (7a^h) were
designed and efficiently synthesized. The dependence of the
affinities for vitamin D receptor (VDR) and vitamin D binding
protein (DBP), as well as the HL-60 cell differentiation-inducing
activity, upon the stereochemistry of the A-ring and at C20 in the
side chain was evaluated.
Conclusions: The binding affinities and potency of the 5,6-trans
and 5,6-cis analogues were enhanced by a 2-methyl substituent in a
certain orientation. Molecular docking studies based upon the X-
ray crystal structure of VDR suggested that the axial 2-methyl
group would be accommodated in a pocket surrounded by
hydrophobic amino acid residues in the ligand binding domain,
resulting in enhanced interaction. ß 2001 Elsevier Science Ltd.
All rights reserved.
Keywords: Cell di¡erentiation; Chemical synthesis ; Molecular
modeling; 5,6-trans-Vitamin D; Vitamin D receptor
1. Introduction
The hormonally active form of vitamin D, 1K,25-dihy-
droxyvitamin D3 (1, Fig. 1), dominates the cell cycle in
many malignant cells, regulating proliferation, di¡erentia-
tion and apoptosis, in addition to its classical role in cal-
cium and phosphorus homeostasis [1]. Such a wide variety
of activities has hampered the clinical application of 1 and
has stimulated chemical and biological research to ¢nd
analogues with selective activity pro¢les as candidate ther-
apeutic agents, as well as to de¢ne its molecular mode of
action [2]. Most of the biological activities of 1 are con-
sidered to be mediated by a ligand-inducible transcription
factor, vitamin D receptor (VDR), which belongs to the
nuclear receptor superfamily. The speci¢c interaction of
ligands with the ligand binding domain (LBD) of VDR
has been the focus of attention in recent years, since it
triggers the whole sequence of actions. In order to inves-
tigate the structure^activity relationships for this interac-
tion, a number of analogues have been synthesized and
biologically evaluated [3]. For the reasons of synthetic
convenience and for metabolic studies of the inactivation
process, many of the analogues synthesized so far were
altered in the side chain, providing useful analogues with
high or selective activity. Among them, 20-epi-1K,25-dihy-
droxyvitamin D3 is noteworthy due to its high activity in
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cell di¡erentiation with a relatively low calcemic e¡ect,
having a clearly distinct biological pro¢le from its parent
hormone 1 [4,5]. This 20-epimerization, combined with
other modi¢cations in the side chain, led to the highly
potent cell di¡erentiation-inducing and immunosuppres-
sive analogue, 20-epi-22-oxa-1K,25-dihydroxy-24,26,27-tri-
homovitamin D3 (KH-1060) [4].
The A-ring moiety of 1, which bears two critical hy-
droxyl groups on the six-membered ring, is of recent in-
terest for metabolic studies as well as for synthesis of
analogues [6]. The con¢gurations of the two hydroxyl
groups on the A-ring in the natural hormone are 1K and
3L (vitamin D numbering system). Epimerization of either
the 1- or 3-hydroxyl group results in a marked reduction
of VDR binding activity [7]. Modi¢cation in the A-ring
provided characteristic analogues, such as 2L-(3-hydroxy-
propoxy)-1K,25-dihydroxyvitamin D3 (ED-71), which has
a strong calcium-regulating activity and is considered a
promising candidate for the treatment of osteoporosis
[8,42,43]. A known geometric stereoisomer of 1, 5,6-
trans-1K,25-dihydroxyvitamin D3 (2, Fig. 1) [9], in which
the exocyclic 10(19)-methylene group appears to be trans-
posed to position 4 in a formal sense, has become of in-
terest in connection with the potent A-ring analogue,
1K,25-dihydroxy-19-norvitamin D3 (3, Fig. 1) [10]. In ad-
dition, analogues with the 5,6-trans motif, in combination
with 16-ene modi¢cation, were recently reported to be
promising antiproliferative agents [11].
Okamura et al. reported in 1974 that the A-ring of 1 is
in a rapid equilibrium of two chair conformers, K-form
and L-form, in which the C10(19) double bond is orien-
tated above or below the diene plane of the C5^C6^C7^C8
diene, respectively, by de¢nition (Fig. 2) [12,13]. They pro-
posed that the L-form, in which the 1K-hydroxyl group
occupies the equatorial position, may be responsible for
biological activity, based upon the results obtained with
tachysterol and other related analogues [14]. On the other
hand, recent studies of 19-nor analogues by DeLuca et al.
implied that the axial orientation of the 1K-hydroxyl
group would be necessary for biological activity of vitamin
D compounds [15].
In view of the results of A-ring modi¢cation stated
above, as well as the conformation^activity relationships
in the A-ring, we synthesized all eight possible A-ring dia-
stereomers of 2-methyl-1,25-dihydroxyvitamin D3 (4a^h,
Fig. 3), demonstrating that the potency of the analogues
varies depending upon the con¢gurations not only of the
C1 and C3 hydroxyl groups, but also of the C2 methyl
Fig. 1. Structures of 1K,25-dihydroxyvitamin D3 (1), its 5,6-trans stereoisomer (2) and 19-nor analogue (3).
Fig. 2. The A-ring conformational equilibria of 1 and 2.
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group [16^19]. In particular, 2K-methyl-1K,25-dihydroxy-
vitamin D3 (4a) exhibited four-fold higher VDR a⁄nity
than 1, while its 2-epimer, 2L-methyl-1K,25-dihydroxyvita-
min D3 (4b) showed one-eighth of the a⁄nity of 1. This
simple A-ring modi¢cation yielded for the ¢rst time an
analogue (4a), having the natural side chain of 1, with
signi¢cantly higher VDR binding activity than the parent
hormone. Our research on 2-methyl-20-epi analogues (5a^
h, Fig. 3) also revealed that the combination of 2K-methyl
introduction and 20-epimerization resulted in exceptional-
ly high potency: in the case of 5a, the 20-epimer of 4a, 12-
fold higher in VDR binding, six-fold in in-vivo calcium-
regulating activity and 590-fold in HL-60 cell di¡erentia-
tion-inducing activity [17^20]. Introduction of the 2-meth-
yl group was shown to alter the conformational equilibria
in the A-ring to a certain extent. However, such high VDR
a⁄nity following 2K-methyl substitution could not be ex-
plained by those conformational e¡ects alone.
In our present work, we have designed and synthesized
all possible A-ring stereoisomers of 5,6-trans-2-methyl-
1,25-dihydroxyvitamin D3 (6a^h, Fig. 3) and their 20-epi-
mers (7a^h, Fig. 3) as novel analogues with the 5,6-trans
modi¢cation to gain further insight into the structure^ac-
tivity relationships of the A-ring, as well as to investigate
how these combinations a¡ect the biological activity pro-
¢les. We also conducted computational docking of the 2-
methyl analogues to the LBD of VDR, based upon the
recently solved X-ray crystal structure of a mutant VDR
[21] in order to understand the signi¢cance of 2-methyl
substitution on the A-ring, and we propose possible
binding modes of the highly potent methyl analogues to
VDR.
Fig. 3. Structures of 2-methyl-1,25-dihydroxyvitamin D3 (4a^h), 20-epi-2-methyl-1,25-dihydroxyvitamin D3 (5a^h), 5,6-trans-2-methyl-1,25-dihydroxyvita-
min D3 (6a^h) and 5,6-trans-20-epi-2-methyl-1,25-dihydroxyvitamin D3 (7a^h).
Scheme 1.
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2. Results and discussion
2.1. Synthesis
The 5,6-trans analogues were synthesized from their 5,6-
cis counterparts via the SO2 adducts [22,23]. Scheme 1
exempli¢es the synthesis of 5,6-trans-2L-methyl-1K,25-di-
hydroxyvitamin D3 (6a) from the 5,6-cis isomer (4b).
Treatment of 4b with SO2 gave a 6-epimeric mixture of
the adducts 8. Subsequent removal of SO2 in 8 by ther-
molysis in the presence of NaHCO3 a¡orded 6a in 66%
yield (two steps). In the case of 6a, the 3L-hydroxyl, 2L-
methyl and 1K-hydroxyl groups may function as pseudo
1K-hydroxyl, pseudo 2K-methyl and pseudo 3L-hydroxyl
groups, respectively [14]. The 5,6-trans analogues 6b, 6c,
6d, 6e, 6f, 6g and 6h were synthesized via exactly the same
sequence of reactions from their 5,6-cis counterparts 4a,
4f, 4e, 4d, 4c, 4h and 4g, respectively. The other 5,6-trans-
20-epi analogues (7a^h) were synthesized from the corre-
sponding 5,6-cis-20-epi analogues (5a^h) as described
above for the 20-natural analogues. As a reference com-
pound, 5,6-trans-1K,25-dihydroxyvitamin D3 (2) was pre-
pared and its molar absorptivity was determined [9]. The
hyperchromic e¡ect and red shift observed in the UV
spectrum of 2 compared to 1 can be explained in terms
of the change of the triene structure. Our results are
consistent with those for 5,6-trans-25-hydroxyvitamin D3
[24].
2.2. Conformational analysis
In order to gain information on A-ring conformation^
activity relationships, the solution conformations of the
5,6-trans analogues were examined by means of 1H
NMR analyses together with molecular mechanics calcu-
lation. Since the roles of the two hydroxyl groups at the
C1 and C3 positions appear to be exchanged in the 5,6-
trans analogues, the K-form and L-form are de¢ned as
illustrated in Fig. 2, in which the 3-hydroxyl group is
axially or equatorially orientated, respectively, in the
case of 2. Firstly, the conformation of 2 was analyzed
by 1H NMR using CDCl3 as a solvent in comparison
with 1. The conformational equilibrium of 1 was estimated
to be a ratio of 45:55 in favor of the L-form from the
vicinal coupling constant between H(3K)^H(4L) of 6.7
Hz by the method based upon the data reported for cyclo-
hexanol protons (Jax;ax = 11.1 Hz, Jeq;eq = 2.7 Hz) [25],
which is widely accepted for analysis of the A-ring of
vitamin D compounds [26,27]. In the case of 2, steric re-
pulsion between H(7) and H(19E) in the 5,6-cis com-
pounds is released and the C10(19) exomethylene and
C5^C6^C7^C8 diene can approach planarity, which would
result in the hyperchromic e¡ect and red shift observed in
the UV spectrum of 2 compared to 1. However, the three
vicinal coupling constants of H(1L)^H(2K), H(2L)^H(3K)
and H(3K)^H(4L) in 2, 5.2 Hz, 8.1 Hz and 8.5 Hz, respec-
tively, indicated that both K- and L-forms were involved in
a ratio of 30:70.
On the basis of the results with 2, the 1H NMR spectra
of all the synthesized analogues (6a^h, 7a^h) were ana-
lyzed. The 1H NMR spectra were taken in CDCl3^D2O
to exclude the coupling of H(1) and H(3) with hydroxyl
protons in these cases. Analyses of COSY and decoupling
experiments allowed the assignment of all A-ring signals
and coupling constants. There was no marked di¡erence in
chemical shifts between each pair of the (20R)- and (20S)-
isomers, except for the chemical shifts due to the 20-meth-
yl groups. In every case, the A-ring is in an equilibrium
between two chair conformations, the K- and L-forms
(Fig. 4), as we previously reported in the case of 5,6-cis
analogues [19]. In the case of 1,3-anti diols (a, b, g and h),
the chair conformers in which the 2-methyl group occupies
the equatorial position are favored. On the other hand, the
1,3-syn diols (c, d, e and f) mainly exist in the chair forms
in which the two hydroxyl groups are axially orientated,
because of the intramolecular hydrogen bond. The equi-
librium ratios shown in Fig. 4 were deduced from the
vicinal coupling constants of H(1)^H(2), H(2)^H(3) and
H(3)^H(4). Molecular mechanics calculation using
MM2* was carried out using model compounds lacking
the side chain. As expected, the two chair conformers in-
volved were most stable in each case and the calculated
values of energy di¡erence and equilibrium ratios at 25‡C,
shown in parentheses in Fig. 4, are in good agreement with
the experimental data.
The orientations of the two hydroxyl groups and the 2-
methyl group a¡ect the equilibrium ratio of the 5,6-trans
analogues, and as a result, the equilibrium is biased to
various extents in a direction that depends upon the A-
ring stereochemistry. In the case of isomer a, the 2L-meth-
yl substituent favored the K-form, whereas the 2K-methyl
substituent of isomer b favored the L-form. DeLuca et al.
obtained conformationally locked A-ring analogues by 2-
methyl introduction into 19-nor analogues [15]. The 19-nor
modi¢cation consists of not only deletion of the C10(19)
exomethylene group, but also introduction of two protons
into the C10 position. They reported that 2K-methyl-
1K,25-dihydroxy-19-norvitamin D3 was essentially com-
pletely locked in the K-form, in which the 1K-hydroxyl
group is in the axial position, while 2L-methyl-1K,25-dihy-
droxy-19-norvitamin D3 was locked in the L-form. On the
other hand, our data on the 5,6-trans-2-methyl analogues
(6a^h, 7a^h), as well as the 5,6-cis counterparts (4a^h, 5a^
h), show that 2-methyl introduction yields, instead of con-
formational lock, a mixture of chair conformers, since the
native A-ring with the C10(19) exomethylene groups allow
the axial 2-methyl orientation to a certain extent due to
the planar sp2 carbon at C10.
2.3. Biological evaluation
The biological activities of the synthesized analogues
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Fig. 4. The A-ring conformational equilibria of the 5,6-trans-2-methyl analogues. The numbers show the equilibrium ratio deduced from the 1H NMR
analysis. The calculated ratio at 25‡C and energy di¡erence values (kcal/mol) are shown in parentheses.
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(6a^h, 7a^h) were assessed in comparison with those of the
natural hormone 1, together with its 5,6-trans stereoisomer
2. The results are summarized in Table 1 (the potency of 1
was normalized to 100 in each biological test). The activ-
ities were highly dependent upon the stereochemistry not
only in the A-ring, but also at C20 in the side chain. On
the basis of our previous results with the 5,6-cis-2-methyl
analogues, the present data indicate that the 5,6-trans
modi¢cation acts as a simple transposition of the
C10(19) exocyclic methylene group, and as a result, the
roles of the two hydroxyl groups at the C1 and C3 posi-
tions appeared to be exchanged in the 5,6-trans-2-methyl
analogues [16-20], except for the case of vitamin D binding
protein (DBP) binding. Thus, these hybrid modi¢cations
yielded analogues with unique activity pro¢les.
In the VDR binding assay using bovine thymus [28],
5,6-trans-1K,25-dihydroxyvitamin D3 (2) showed a re-
duced a⁄nity compared to 1 by approximately 100-fold
[9]. In addition, 5,6-trans modi¢cation of the 2-methyl
analogues resulted in a reduction of a⁄nity compared to
each structurally-related 5,6-cis counterpart; for example,
6a showed approximately 50-fold lower a⁄nity than 4a
[16^20]. Among the 5,6-trans-2-methyl analogues with nat-
ural (20R)-con¢guration (6a^h), those having the 3L-hy-
droxyl group (6a^d), which would act as a pseudo 1K-hy-
droxyl group, exhibited higher a⁄nity compared to the
corresponding 3-epimers (6e^h). Introduction of the 2L-
methyl group into 2 to produce 6a elevated the VDR
a⁄nity by approximately 10-fold, while introduction of
the 2K-methyl group to give 6b reduced the potency.
Thus, as in the case of 2K-methyl introduction into
1K,25-dihydroxyvitamin D3 (1), the pseudo 2K-methyl in-
troduction into 5,6-trans-1K,25-dihydroxyvitamin D3 (2),
such as in 6a, enhanced the a⁄nity to VDR. These results
imply that 2-methyl substitution in ‘up’ con¢gurations,
irrespective of 5,6-trans or 5,6-cis arrangement, would
play an important role in enhancing the VDR binding
potency. Transposition of the C10(19) exomethylene
group reduced the a⁄nity, but seemed to have little e¡ect
on the character of each substituent in the A-ring. Similar
trends were found among the 20-epi analogues with (20S)-
con¢guration. The rank order of the VDR a⁄nity among
the 20-epi analogues (7a^h) was essentially the same as
observed among the (20R)-counterparts (6a^h). The
VDR binding potency of 20-epi-1K,25-dihydroxyvitamin
D3 using bovine thymus in comparison with 1, normalized
to 100, was estimated to be 400 by us [29] and 500 by
others [5]. 20-Epimerization of each 5,6-trans-2-methyl iso-
mer elevated the a⁄nity by approximately 3^15-fold.
Thus, 2-methyl introduction and 20-epimerization had ad-
ditive e¡ects on the VDR binding potency.
In the DBP binding assay using rat serum [30], the ana-
logues having the 2K-methyl con¢guration showed higher
a⁄nity than the corresponding 2-epimers, and 20-epimeri-
zation of each isomer decreased the a⁄nity. The strongest
ligand to DBP among vitamin D metabolites was consid-
ered to be 25-hydroxyvitamin D3, and a 1K-hydroxyl
group decreased the a⁄nity to DBP [31]. In the case of
5,6-trans analogues, however, isomers having the 3L-hy-
droxyl group, which would act as a pseudo 1K-hydroxyl
group, proved to be better binders than those having the
3K-hydroxyl group. The C10(19) exomethylene group of
5,6-trans isomers seems to play an important role in the
DBP binding and di¡erentiates the roles of the two hy-
droxyl groups in the A-ring.
Cell di¡erentiation-inducing activity of the analogues
towards HL-60 cells at 1038 M was assessed in terms of
expression of cell surface CD11b [32]. Fig. 5 indicates that
the analogues 6a, 7a and 7b exhibited a potency compa-
rable to or even higher than that of the natural hormone
1. It is noteworthy that 7e was signi¢cantly active in spite
of having the 3K-hydroxyl con¢guration (i.e., the pseudo
1L-hydroxyl con¢guration), which should impart low or
no activity. Recent studies of A-ring analogues, in partic-
ular combined with side chain modi¢cations, show that
the transcriptional potency is sometimes elevated even
when the VDR binding a⁄nity is low [44-46]. In order
to examine further the potency as di¡erentiators, the
Table 1
Relative biological activity of the 5,6-trans-2-methyl analoguesa
(20R) VDRb DBPc HL-60d (20S) VDR DBP HL-60
1 100 100 100
2 0.8 14 47
6a 8.6 7.7 235 7a 45 1.0 333
6b 0.4 17 7 7b 1 0.7 53
6c 0.1 34 NDe 7c 0.8 2.1 36
6d 6 0.01 81 ND 7d 0.03 1.8 ND
6e 0.04 6.0 ND 7e 0.5 6 0.1 38
6f 0.013 11 ND 7f 0.2 6 0.1 ND
6g 0.03 8.8 ND 7g 0.2 6 0.1 ND
6h 6 0.01 28 ND 7h 0.08 0.4 ND
aThe potencies of 1K,25-dihydroxyvitamin D3 (1) are taken as 100.
bBovine thymus.
cRat serum.
dHL-60 cell di¡erentiation was assessed in terms of expression of CD11b.
eNot determined.
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dose dependency of selected analogues, 2, 6a, 6b, 7a, 7b, 7c
and 7e, was investigated (Fig. 6). The data are summarized
as relative potencies with respect to 1, de¢ned as 100, in
Table 1. The cell di¡erentiation-inducing potency of 5,6-
trans-1K,25-dihydroxyvitamin D3 2 was approximately
half that of the natural hormone 1. The analogue 6a
showed 2.4-fold higher activity than 1, whereas its 2-epi-
mer, 6b, exhibited 7% of the activity of the natural hor-
mone 1. The potency of the isomers 6a,b was enhanced by
20-epimerization, but to a lesser extent than in the case of
5,6-cis-2-methyl analogues [16^20]. Those results might be
explained by a di¡erence in DBP binding, which is be-
lieved to correlate with availability of the compounds to
target cells [31]. Among the four analogues with (20S)-
con¢guration, 7a exhibited 3.3 times higher potency than
the natural hormone 1. Epimerization of the C1, C2 or C3
substituent in 7a yields 7c, 7b and 7e, respectively, all of
which showed similar cell di¡erentiation-inducing activity.
As regards the activity of 20-epi-1K,25-dihydroxyvitamin
D3, epimerization of either the C1- or C3-hydroxyl group
dramatically decreases cell di¡erentiation-inducing activity
by 360 times for C1 and 17 times for C3 [29]. In the case
of 5,6-trans-2-methyl analogues, however, the bene¢cial
e¡ects of ‘up’ methyl introduction seemed to be well re-
tained irrespective of C1 or C3 stereochemistry, and as a
result, both the 1-epimer (7c) and 3-epimer (7e) of 7a
showed signi¢cant cell di¡erentiation-inducing activity
(approximately one-third of the activity of the natural
hormone 1).
2.4. Docking modes of the A-ring analogues to vitamin D
receptor
Interaction of the side chains of vitamin D analogues
with VDR is well documented, and Yamada et al. showed
that potential side chain structures, as well as their func-
tions, can be predicted by conformational analysis using
molecular mechanics [33]. Molecular modeling studies of
the LBD of human VDR have reinforced the above con-
cept [34]. Furthermore, di¡erential interaction of com-
pounds having the natural side chain and their 20-epimers
has been demonstrated based upon the X-ray structures of
mutant human VDR complexed with 20-epi analogues
[35]. In contrast, little is known about the structure^activ-
ity relationships of the A-ring, irrespective of 5,6-cis or
5,6-trans structure.
Besides the conformational problems in the A-ring, ad-
ditional e¡ects of 2-methyl substitution, which gave the
analogues characteristic activity pro¢les, appeared to exist.
The present data on the 5,6-trans-2-methyl analogues (6a^
h, 7a^h) have shed some light on the signi¢cance of 2-
methyl introduction. Among the epimeric pairs di¡ering
only in the con¢guration at the C2 position, every 2L-
methyl (i.e., pseudo 2K-methyl) analogue exhibited higher
VDR binding potency than the corresponding 2K-methyl
(i.e., pseudo 2L-methyl) analogue by 10^60-fold. This may
mean that an ‘upper’ methyl group plays an important
role in elevation of the VDR binding potency.
The amino acid residues in the LBD of VDR are essen-
tially conserved among mammals, including bovine, por-
cine and human. The recently solved X-ray crystal struc-
ture of a mutant human VDR complexed with 1
demonstrated that the A-ring of 1 was docked to the
LBD of VDR in its L-form [21]. The equatorial 1K-hy-
droxyl group of 1 formed two hydrogen bonds with Ser-
237(H3) and Arg-274(H5), while the axial 3L-hydroxyl
Fig. 6. HL-60 cell di¡erentiation-inducing activity of the 5,6-trans-2-
methyl analogues. HL-60 cells were treated with between 10311 M and
1037 M 1K,25-dihydroxyvitamin D3 (1) or the analogues (2, 6a, 6b, 7a,
7b, 7c, 7e) for 72 h. Cell di¡erentiation was assessed in terms of expres-
sion of CD11b. Vehicle average is denoted by a solid diamond on the
y-axis. The data are summarized as relative potencies with respect to 1,
de¢ned as 100, in Table 1.
Fig. 5. HL-60 cell di¡erentiation-inducing activity of the 5,6-trans-2-methyl analogues. HL-60 cells were treated with 1038 M 1K,25-dihydroxyvitamin
D3 (1) or the analogues (2, 6a^h, 7a^h) for 72 h. Cell di¡erentiation was assessed in terms of expression of CD11b.
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group of 1 formed two hydrogen bonds with Ser-278(H5)
and Tyr-143. Interestingly, the experimental data show
that there is additional space near the C2 position, which
could accommodate a rather bulky substituent. The cavity
is long, reaching the surface of the receptor. In the vicinity
of the C2 position in the A-ring, the natural hormone 1 is
surrounded by hydrophobic amino acid residues, such as
Leu-233(H3), Tyr-236(H3) and Phe-150.
Among the 5,6-cis analogues, 2L-methyl-1K,25-dihy-
droxyvitamin D3 (4b), the A-ring of which mainly exists
in the L-form, showed a slightly reduced VDR a⁄nity [19].
The VDR binding potencies of 2L-alkyl-substituted ana-
logues were reported by us and by others using bovine
thymus VDR. The estimates for 2L-methyl- (4b), 2L-ethyl-
and 2L-propyl-1K,25-dihydroxyvitamin D3, relative to 1
normalized to 100, are 13, 10 and 26, respectively [16^
19,36]. Since the natural ligand 1 was bound in its L-
form with additional space near position 2, these 2L-sub-
stituted analogues would interact with the LBD of VDR
in their L-forms with the 2L-substituents in the equatorial
positions without unfavorable structural dispositions. In-
deed, the VDR binding potency was essentially unaltered
among those three analogues.
Binding modes of the 2K-substituted 5,6-cis analogues,
however, could di¡er from those of 2L-substituted ana-
logues. We have synthesized a series of 2K-substituted
analogues having various lengths of 2-alkyl, 2-(g-hydroxy-
alkyl) and 2-(g-hydroxyalkoxy) groups, and found that
the 2K-substituted analogues with terminal hydroxyl
groups exhibited a marked elevation in VDR binding po-
tency [37,38]. Due to the long 2K-substituent, the A-ring
of 2K-(3-hydroxypropoxy)-1K,25-dihydroxyvitamin D3,
which showed 1.8-fold higher VDR a⁄nity than 1, would
adopt the K-form to dock into the LBD of VDR, facilitat-
ing an additional hydrogen bond network involving its
terminal hydroxyl group with Asp-144 and Tyr-236 [38].
This, combined with two other molecular modeling results
on the LBD of VDR [34,39], may mean that vitamin D
analogues could be accommodated in the LBD of the
receptor in either K- or L-form.
Fig. 7. Overlay of the modeled VDR/2K-methyl-1K,25-dihydroxyvitamin D3 (4a ; carbon atoms in yellow) complex with the VDR/1K,25-dihydroxyvita-
min D3 (1 ; carbon atoms in green) structure [21] in the LBD. Hydrogen bonds are drawn as dotted lines. The axial 2-methyl group of 4a makes a fa-
vorable contact with a hydrophobic region surrounded by Leu-233, Tyr-236 and Phe-150. Of the 32 amino acid residues used for the calculation, only
those in the close vicinity of the A-ring are included for clarity.
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The 2K-methyl introduction into the A-ring of 1 (as in
4a), which favored the K-form, caused a marked elevation
in VDR a⁄nity [19]. The VDR binding potencies of 2K-
methyl- (4a), 2K-ethyl- and 2K-propyl-1K,25-dihydroxyvi-
tamin D3 relative to 1 (normalized to 100) were estimated
to be 400, 40 and 20, respectively, by using bovine thymus
VDR [16^19,37]. These 2K-substituted analogues could in-
teract with the LBD of VDR in their K-forms with the 2K
substituents in the equatorial positions as stated above in
the case of 2K-(3-hydroxypropoxy)-1K,25-dihydroxyvita-
min D3. However, the VDR a⁄nity of 2K-methyl-1K,25-
dihydroxyvitamin D3 (4a) was considerably high among
the three analogues compared with the corresponding
2L-alkyl-substituted counterparts, each of which showed
similar a⁄nity. We speculated that 2K-methyl-1K,25-dihy-
droxyvitamin D3 (4a) would bind to the LBD in its L-
form, essentially retaining the hydrogen bond networks
observed in the X-ray-solved structure of 1 in the receptor.
In this case, the axial 2K-methyl group would ¢t into the
‘upper’ hydrophobic pocket. Molecular mechanics calcu-
lations based upon the X-ray crystal structure [21] support
the above hypothesis. Fig. 7 depicts a superposition of 2K-
methyl-1K,25-dihydroxyvitamin D3 (4a) and the natural
hormone (1) bound to the LBD of VDR. A noteworthy
feature is the lipophilic extension of 4a provided by the
axial 2K-methyl substituent which reaches closer to the
‘upper’ lipophilic pocket formed by Leu-233(H3), Tyr-
236(H3) and Phe-150, leading to enhanced interaction.
The axial 2K-methyl group would be in the close vicinity
of the aromatic amino acid residues Tyr-236(H3) and Phe-
150, which suggests the involvement of CH/Z interaction
[40], in addition to the steric e¡ects. This binding mode
provides a basis for the structure^activity relationships of
the 2-methyl-substituted analogues.
The VDR binding potency of 5,6-trans-1K,25-dihydroxy-
vitamin D3 (2) was reduced by approximately 100-fold in
Fig. 8. Overlay of the modeled VDR/5,6-trans-methyl-1K,25-dihydroxyvitamin D3 (2 ; carbon atoms in yellow) complex with the VDR/1K,25-dihydroxy-
vitamin D3 (1 ; carbon atoms in green) structure [21] in the LBD. Hydrogen bonds are drawn as dotted lines. Due to the transposed C10(19) exomethy-
lene group, the A-ring of 2 would be forced outward by Cys-288, resulting in a less favorable binding mode in terms of the C1 and C3 hydroxyl
groups. Of the 32 amino acid residues used for the calculation, only those in the close vicinity of the A-ring are included for clarity.
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comparison with 1. This may be explained by unfavorable
steric contacts of the transposed exomethylene group with
the amino acid residues of the LBD of VDR. Superim-
posed docking models of 1 and 2 show that the C10(19)
exomethylene group of 2 approaches the side chain of
Cys-288(L-sheet), which causes a signi¢cantly less favor-
able binding mode (Fig. 8). In the case of 5,6-trans-2-
methyl analogues, the axial 2-methyl group would contact
the ‘upper’ lipophilic pocket, which indeed resulted in an
approximately 10-fold elevation of the VDR a⁄nity as
seen in 6a compared to 2. In this situation, the A-ring
of 6a would adopt the L-form, retaining the hydrogen
bond networks of 2 in terms of the equatorial 3-hydroxyl
group and the axial 1-hydroxyl group. Among the 19-nor
compounds, the VDR binding potency of 2K-methyl-
1K,25-dihydroxy-19-norvitamin D3 was reported to be
22, relative to 1 normalized to 100, and that of its 2-epi-
mer, 2L-methyl-1K,25-dihydroxy-19-norvitamin D3, to be
2.6 by using porcine intestinal VDR [15]. Similarly, the
axial 2-methyl substituent of 2K-methyl-1K,25-dihydroxy-
19-norvitamin D3 could interact with the ‘upper’ lipophilic
pocket. However, the lack of the C10(19) exomethylene
group would make the A-ring of the 19-nor analogues
rather compact and further intrusion into the bottom of
the cavity might a¡ord alternative binding modes. Further
studies are required to assess the binding modes of the 19-
nor analogues, taking into account the water molecules
involved in this cavity [41].
3. Signi¢cance
All possible A-ring stereoisomers of 5,6-trans-2-methyl-
1,25-dihydroxyvitamin D3 (6a^h) and their 20-epimers
(7a^h) were designed and e⁄ciently synthesized. Biological
evaluation of the 5,6-trans analogues revealed that pseudo
2K-methyl introduction into the parent 5,6-trans-1K,25-di-
hydroxyvitamin D3 (2) enhanced the potency, as in the
case of the 2K-methyl introduction into 1K,25-dihydroxy-
vitamin D3 (1), which reinforced the idea of a bene¢cial
e¡ect of the ‘up’ methyl introduction. The combined mod-
i¢cation of pseudo 2K-methyl introduction and 20-epimer-
ization had additive e¡ects on VDR binding activity.
Transposition of the C10(19) exomethylene group, on
the other hand, di¡erentially a¡ected DBP binding and
HL-60 cell di¡erentiation-inducing activity of the 2-methyl
analogues. Molecular docking studies of the analogues in
the LBD of VDR based upon the recently solved X-ray
crystal structure of mutant VDR suggested that the axial
2-methyl substituent would contact a hydrophobic region,
resulting in enhanced interaction. The putative binding
modes of the potent 2-methyl analogues well explained
the results of biological evaluation of these analogues.
These binding models should provide a new design con-
cept for VDR ligands and stimulate structure^function
studies focused upon the protein^ligand complex.
4. Materials and methods
4.1. Chemical synthesis
Melting points were determined by using a Yanagimoto hot-
stage melting point apparatus and are uncorrected. NMR spectra
were recorded on a JEOL GSX-400 spectrometer. Chemical shifts
are expressed in ppm relative to tetramethylsilane. Mass spectra
(MS) and high-resolution mass spectra (HRMS) were recorded
on a JMS-SX 102A. Infrared spectra were recorded on a Jasco
FT/IR-8000 spectrometer and are expressed in cm31. Ultraviolet
spectra were recorded with a Shimadzu UV-1600 spectrophotom-
eter. Optical rotations were determined by using a Jasco DIP-370
digital polarimeter. Elemental analyses were carried out in the
Microanalytical Laboratory, Faculty of Pharmaceutical Sciences,
University of Tokyo, and were within 0.3% of the theoretical
values.
4.1.1. (5E,7E)-(1S,3R)-9,10-Seco-5,7,10(19)-cholestatriene-
1,3,25-triol (2)
(5Z,7E)-(1S,3R)-9,10-Seco-5,7,10(19)-cholestatriene-1,3,25-triol
(1) (16.5 mg, 0.04 mmol) was dissolved in liquid SO2 (V10 ml),
and the solution was re£uxed at the boiling temperature of SO2
for 30 min. After SO2 was evaporated, the residue was dissolved
in ethanol (2 ml), and NaHCO3 (17 mg, 0.2 mmol) was added.
The resulting mixture was heated at 90‡C for 4 h. After the
solvent was evaporated, brine was added to the mixture and
the whole was extracted with ethyl acetate. The organic layer
was dried over magnesium sulfate, ¢ltered and concentrated.
The crude product was puri¢ed by silica gel preparative TLC
(ethyl acetate) to give the vitamin (13.7 mg, 83%) as a white solid.
Further puri¢cation was conducted using reversed-phase recycle
HPLC (YMC-Pack ODS column, 20 mmU150 mm, 9.0 ml/min,
acetonitrile :water = 8:2), followed by recrystallization from ethyl
acetate to give analytically pure vitamin as colorless ¢ne prisms:
mp 175^176‡C (recryst. from ethyl acetate) ; [K]27D +159 (c = 0.059,
CHCl3); UV (EtOH) Vmax 274 nm (O : 23 500), Vmin 230 nm (O :
4900); 1H NMR (400 MHz, CDCl3) N 0.56 (3 H, s), 0.94 (3 H, d,
J = 6.1 Hz), 1.22 (6 H, s), 2.28 (1 H, dd, J = 13.4, 8.5 Hz), 2.86
(2 H, m), 4.23 (1 H, dddd, J = 8.4, 8.1, 4.0, 3.7 Hz), 4.49 (1 H, dd,
J = 5.2, 4.0 Hz), 4.97 (1 H, s), 5.12 (1 H, s), 5.88 (1 H, d, J = 11.6
Hz), 6.58 (1 H, d, J = 11.6 Hz); 13C NMR (100 MHz, CDCl3)
N 12.1 (q), 18.8 (q), 20.8 (t), 22.3 (t), 23.5 (t), 27.6 (t), 29.1 (t), 29.2
(q), 29.4 (q), 33.6 (d), 36.1 (t), 37.8 (t), 40.4 (t), 42.0 (t), 44.4 (t),
46.0 (s), 56.5 (d), 56.6 (d), 65.9 (d), 71.1 (d), 73.4 (s), 109.6 (t),
115.9 (d), 123.4 (d), 132.0 (s), 132.6 (d), 151.7 (s) ; FTIR (neat)
3422, 2936, 2874, 2361, 2334, 1716, 1651, 1558, 1456, 1375, 1261,
1153, 1051, 908 cm31 ; MS 416 [M], 398 [M3H2O], 380
[M32H2O] ; HRMS calcd. for [C27H44O3] 416.3263, found
416.3260; anal. calcd. for C27H44O3W1/4H2O: C, 77.00; H,
10.65. Found: C, 76.91; H.10.43.
4.1.2. (5E,7E)-(1S,2R,3R)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (6a)
(5Z,7E)-(1S,2R,3R)-2-Methyl-9,10-seco-5,7,10(19)-cholesta-
triene-1,3,25-triol (4b) (7.0 mg, 0.016 mmol) was dissolved in liq-
uid SO2 (V10 ml), and the solution was re£uxed at the boiling
temperature of SO2 for 1 h. After SO2 was evaporated, the res-
idue was dissolved in ethanol (2 ml), and NaHCO3 (6.8 mg, 0.081
mmol) was added. The resulting mixture was heated at 90‡C for
1 h. After the solvent was evaporated, brine was added to the
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mixture and the whole was extracted with ethyl acetate. The
organic layer was dried over magnesium sulfate, ¢ltered and con-
centrated. The crude product was puri¢ed by silica gel prepara-
tive TLC (ethyl acetate) to give 6a (4.6 mg, 66%) as a colorless
solid. Further puri¢cation for biological evaluation was con-
ducted by using reversed-phase recycle HPLC (YMC-Pack ODS
column, 20 mmU150 mm, 9.0 ml/min, acetonitrile:water = 8:2):
UV (EtOH) Vmax 272 nm, Vmin 230 nm; 1H NMR (400 MHz,
CDCl3^D2O) N 0.56 (3 H, s), 0.94 (3 H, d, J = 6.4 Hz), 1.08 (3 H,
d, J = 7.0 Hz), 1.22 (6 H, s), 1.94 (1 H, ddq, J = 7.2, 3.3, 7.0 Hz),
2.56 (1 H, dd, J = 13.7, 3.4 Hz), 2.60 (1 H, dd, J = 14.6, 6.7 Hz),
2.83 (1 H, dd, J = 11.5, 4.4 Hz), 4.13 (1 H, d, J = 7.2 Hz), 4.14
(1 H, dt, J = 6.7, 3.4 Hz), 5.01 (1 H, s), 5.15 (1 H, s), 5.87 (1 H, d,
J = 11.6 Hz), 6.61 (1 H, d, J = 11.6 Hz); MS 430 [M], 412
[M3H2O], 394 [M32H2O], 379 [M32H2O3Me] ; HRMS
calcd. for [C28H46O3] 430.3447, found 430.3446.
4.1.3. (5E,7E)-(1S,2S,3R)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (6b)
This compound was obtained from 4a by the same procedure
as described for 6a : UV (EtOH) Vmax 273 nm, Vmin 230 nm; 1H
NMR (400 MHz, CDCl3^D2O) N 0.57 (3 H, s), 0.95 (3 H, d,
J = 6.4 Hz), 1.14 (3 H, d, J = 7.0 Hz), 1.22 (6 H, s), 1.83 (1 H,
ddq, J = 9.0, 3.2, 7.0 Hz), 2.13 (1 H, dd, J = 13.9, 9.0 Hz), 2.85
(1 H, dd, J = 12.0, 4.2 Hz), 3.02 (1 H, dd, J = 14.0, 4.3 Hz), 3.85
(1 H, dt, J = 4.6, 9.0 Hz), 4.29 (1 H, d, J = 3.1 Hz), 4.93 (1 H, s),
5.12 (1 H, d, J = 1.8 Hz), 5.89 (1 H, d, J = 11.6 Hz), 6.55
(1 H, dd, J = 11.6, 0.9 Hz); MS 430 [M], 412 [M3H2O],
394 [M32H2O], 379 [M32H2O3Me] ; HRMS calcd. for
[C28H46O3] 430.3447, found 430.3447.
4.1.4. (5E,7E)-(1R,2R,3R)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (6c)
This compound was obtained from 4f by the same procedure as
described for 6a : UV (EtOH) Vmax 274 nm, Vmin 231 nm; 1H
NMR (400 MHz, CDCl3^D2O) N 0.57 (3 H, s), 0.94 (3 H, d,
J = 6.4 Hz), 1.22 (6 H, s), 1.24 (3 H, d, J = 7.0 Hz), 1.92 (1 H,
ddq, J = 2.4, 2.5, 7.0 Hz), 2.27 (1 H, dd, J = 14.7, 3.1 Hz), 2.88
(1 H,dd, J = 12.8, 3.7 Hz), 3.05 (1 H, dd, J = 14.6, 3.7 Hz), 3.97
(1 H, ddd, J = 2.4, 3.1, 3.7 Hz), 4.21 (1 H, d, J = 2.5 Hz), 4.90
(1 H, d, J = 1.8 Hz), 5.10 (1 H, d, J = 1.8 Hz), 5.91 (1 H, d,
J = 11.3 Hz), 6.67 (1 H, d, J = 11.3 Hz); MS 430 [M], 412
[M3H2O], 394 [M32H2O], 379 [M32H2O3Me] ; HRMS
calcd. for [C28H46O3] 430.3447, found 430.3449.
4.1.5. (5E,7E)-(1R,2S,3R)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (6d)
This compound was obtained from 4e by the same procedure
as described for 6a : UV (EtOH) Vmax 271 nm, Vmin 229 nm; 1H
NMR (400 MHz, CDCl3^D2O) N 0.57 (3 H, s), 0.95 (3 H, d,
J = 6.2 Hz), 1.03 (3 H, d, J = 7.0 Hz), 1.22 (6 H, s), 1.89 (1 H,
ddq, J = 5.5, 4.8, 7.0 Hz), 2.06 (1 H, dd, J = 15.0, 5.8 Hz), 2.65
(1 H, dd, J = 15.0, 4.8 Hz), 2.87 (1 H, dd, J = 12.2, 3.7 Hz), 3.71
(1 H, dt, J = 5.8, 4.8 Hz), 3.98 (1 H, d, J = 5.5 Hz), 4.97 (1 H, s),
5.17 (1 H, s), 5.89 (1 H, d, J = 11.7 Hz), 6.62 (1 H, d, J = 11.7
Hz); MS 430 [M], 412 [M3H2O], 394 [M32H2O], 379
[M32H2O3Me] ; HRMS calcd. for [C28H46O3] 430.3447, found
430.3448.
4.1.6. (5E,7E)-(1S,2R,3S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (6e)
This compound was obtained from 4d by the same procedure
as described for 6a : UV (EtOH) Vmax 271 nm, Vmin 229 nm; 1H
NMR (400 MHz, CDCl3^D2O) N 0.57 (3 H, s), 0.95 (3 H, d,
J = 6.4 Hz), 1.03 (3 H, d, J = 7.0 Hz), 1.22 (6 H, s), 1.91 (1 H,
ddq, J = 5.1, 4.8, 7.0 Hz), 2.61 (1 H, dd, J = 15.0, 4.4 Hz), 2.65
(1 H, dd, J = 15.0, 5.1 Hz), 2.86 (1 H, dd, J = 11.9, 3.7 Hz), 3.74
(1 H, dt, J = 4.4, 5.1 Hz), 4.00 (1 H, d, J = 5.1 Hz), 4.97 (1 H, s),
5.18 (1 H, d, J = 1.6 Hz), 5.90 (1 H, d, J = 11.6 Hz), 6.62 (1 H, d,
J = 11.6 Hz); MS 430 [M], 412 [M3H2O], 394 [M32H2O],
379 [M32H2O3Me] ; HRMS calcd. for [C28H46O3] 430.3447,
found 430.3444.
4.1.7. (5E,7E)-(1S,2S,3S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (6f)
This compound was obtained from 4c by the same procedure
as described for 6a : UV (EtOH) Vmax 274 nm, Vmin 231 nm; 1H
NMR (400 MHz, CDCl3^D2O) N 0.57 (3 H, s), 0.95 (3 H, d,
J = 6.4 Hz), 1.22 (6 H, s), 1.24 (3 H, d, J = 7.0 Hz), 1.93 (1 H,
ddq, J = 2.4, 2.1, 7.0 Hz), 2.28 (1 H, dd, J = 14.6, 2.4 Hz), 2.88
(1 H, dd, J = 12.2, 3.7 Hz), 3.06 (1 H, dd, J = 14.6, 3.7 Hz), 3.98
(1 H, ddd, J = 3.7, 2.4, 2.1 Hz), 4.21 (1 H, d, J = 2.1 Hz), 4.91
(1 H, d, J = 1.8 Hz), 5.12 (1 H, d, J = 1.8 Hz), 5.92 (1 H, d,
J = 11.3 Hz), 6.67 (1 H, d, J = 11.3 Hz); MS 430 [M], 412
[M3H2O], 394 [M32H2O], 379 [M32H2O3Me] ; HRMS
calcd. for [C28H46O3] 430.3447, found 430.3448.
4.1.8. (5E,7E)-(1R,2R,3S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (6g)
This compound was obtained from 4h by the same procedure
as described for 6a : UV (EtOH) Vmax 275 nm, Vmin 231 nm; 1H
NMR (400 MHz, CDCl3^D2O) N 0.57 (3 H, s), 0.95 (3 H, d,
J = 6.4 Hz), 1.14 (3 H, d, J = 7.0 Hz), 1.22 (6 H, s), 1.83 (1 H,
ddq, J = 9.2, 3.1, 7.0 Hz), 2.13 (1 H, dd, J = 14.0, 9.2 Hz), 2.85
(1 H, dd, J = 11.9, 4.0 Hz), 3.01 (1 H, dd, J = 14.0, 4.5 Hz), 3.87
(1 H, dt, J = 4.5, 9.2 Hz), 4.30 (1 H, d, J = 3.1 Hz), 4.93 (1 H, d,
J = 1.8 Hz), 5.11 (1 H, d, J = 1.8 Hz), 5.89 (1 H, d, J = 11.6 Hz),
6.55 (1 H, d, J = 11.6 Hz); MS 430 [M], 412 [M3H2O],
394 [M32H2O], 379 [M32H2O3Me] ; HRMS calcd. for
[C28H46O3] 430.3447, found 430.3442.
4.1.9. (5E,7E)-(1R,2S,3S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (6h)
This compound was obtained from 4g by the same procedure
as described for 6a : UV (EtOH) Vmax 274 nm, Vmin 232 nm; 1H
NMR (400 MHz, CDCl3^D2O) N 0.57 (3 H, s), 0.95 (3 H, d,
J = 6.4 Hz), 1.08 (3 H, d, J = 7.0 Hz), 1.22 (6 H, s), 1.93 (1 H,
ddq, J = 8.0, 3.4, 7.0 Hz), 2.53 (1 H, dd, J = 14.3, 3.4 Hz), 2.61
(1 H, dd, J = 14.3, 5.8 Hz), 2.85 (1 H, dd, J = 12.2, 3.7 Hz), 4.15
(2 H, m), 5.01 (1 H, s), 5.15 (1 H, s), 5.86 (1 H, d, J = 11.3 Hz),
6.60 (1 H, d, J = 11.3 Hz); MS 430 [M], 412 [M3H2O],
394 [M32H2O], 379 [M32H2O3Me] ; HRMS calcd. for
[C28H46O3] 430.3447, found 430.3443.
4.1.10. (5E,7E)-(1S,2R,3R,20S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (7a)
This compound was obtained from 5d by the same procedure
as described for 6a : UV (EtOH) Vmax 272 nm, Vmin 230 nm; 1H
NMR (400 MHz, CDCl3) N 0.56 (3 H, s), 0.86 (3 H, d, J = 6.4
Hz), 1.09 (3 H, d, J = 7.0 Hz), 1.22 (6 H, s), 1.88 (1 H, m), 1.95
(1 H, ddq, J = 7.6, 3.4, 7.0 Hz), 2.53 (1 H, dd, J = 14.3, 4.0 Hz),
2.60 (1 H, dd, J = 14.6. 7.0 Hz), 4.13 (1 H, d, J = 7.6 Hz), 4.17
(1 H, ddd, J = 7.0, 4.0, 3.4 Hz), 5.01 (1 H, s), 5.16 (1 H, s), 5.87
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(1 H, d, J = 11.6 Hz), 6.61 (1 H, d, J = 11.6 Hz); MS 430 [M],
412 [M3H2O], 379 [M3H2O3Me] ; HRMS calcd. for
[C28H46O3] 430.3447, found 430.3445.
4.1.11. (5E,7E)-(1S,2S,3R,20S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (7b)
This compound was obtained from 5a by the same procedure
as described for 6a : 1H NMR (400 MHz, CDCl3) N 0.56 (3 H, s),
0.86 (3 H, d, J = 6.4 Hz), 1.14 (3 H, d, J = 7.0 Hz), 1.22 (6 H, s),
1.83 (1 H, m), 3.01 (1 H, dd, J = 14.3, 5.2 Hz), 3.84 (1 H, m), 4.29
(1 H, m), 4.93 (1 H, d, J = 2.1 Hz), 5.12 (1 H, d, J = 2.1 Hz), 5.89
(1 H, d, J = 11.4 Hz), 6.54 (1 H, d, J = 11.4 Hz); MS 430 [M],
412 [M3H2O], 394 [M32H2O], 379 [M32H2O3Me] ;
HRMS calcd. for [C28H46O3] 430.3447, found 430.3473.
4.1.12. (5E,7E)-(1R,2R,3R,20S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (7c)
This compound was obtained from 5f by the same procedure as
described for 6a : UV (EtOH) Vmax 274 nm, Vmin 231 nm; 1H
NMR (400 MHz, CDCl3) N 0.57 (3 H, s), 0.86 (3 H, d, J = 6.4
Hz), 1.21 (6 H, s), 1.24 (3 H, d, J = 7.0 Hz), 2.28 (1 H, br. d,
J = 14.6 Hz), 2.88 (1 H, dd, J = 12.4, 3.7 Hz), 3.04 (1 H, dd,
J = 15.0, 4.0 Hz), 3.97 (1 H, m), 4.21 (1 H, m), 4.90 (1 H, d,
J = 1.5 Hz), 5.10 (1 H, d, J = 1.8 Hz), 5.91 (1 H, d, J = 11.6
Hz), 6.66 (1 H, d, J = 11.6 Hz); MS 430 [M], 412 [M3H2O],
394 [M32H2O], 379 [M32H2O3Me] ; HRMS calcd. for
[C28H46O3] 430.3447, found 430.3423.
4.1.13. (5E,7E)-(1R,2S,3R,20S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (7d)
This compound was obtained from 5e by the same procedure
as described for 6a : UV (EtOH) Vmax 270 nm, Vmin 230 nm; 1H
NMR (400 MHz, CDCl3) N 0.57 (3 H, s), 0.86 (3 H, d, J = 6.4
Hz), 1.03 (3 H, d, J = 7.0 Hz), 1.22 (6 H, s), 1.87 (1 H, m), 2.60
(1 H, dd, J = 15.3, 6.1 Hz), 2.64 (1 H, dd, J = 15.3, 4.6 Hz), 2.87
(1 H, dd, J = 11.9, 4.0 Hz), 3.71 (1 H, m), 3.98 (1 H, m), 4.97
(1 H, s), 5.17 (1 H, d, J = 1.8 Hz), 5.90 (1 H, d, J = 11.6 Hz), 6.61
(1 H, d, J = 11.6 Hz); MS 430 [M], 412 [M3H2O], 397
[M3H2O3Me] ; HRMS calcd. for [C28H46O3] 430.3447, found
430.3465.
4.1.14. (5E,7E)-(1S,2R,3S,20S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (7e)
This compound was obtained from 5d by the same procedure
as described for 6a : UV (EtOH) Vmax 271 nm, Vmin 229 nm; 1H
NMR (400 MHz, CDCl3) N 0.56 (3 H, s), 0.86 (3 H, d, J = 6.4
Hz), 1.03 (3 H, d, J = 7.4 Hz), 1.21 (6 H, s), 2.62 (2 H, m), 2.86
(1 H, m), 3.75 (1 H, m), 4.00 (1 H, m), 4.97 (1 H, s), 5.18 (1 H, d,
J = 1.8 Hz), 5.90 (1 H, d, J = 11.6 Hz), 6.62 (1 H, d, J = 11.9 Hz);
MS 430 [M], 412 [M3H2O], 394 [M32H2O], 379
[M32H2O3Me] ; HRMS calcd. for [C28H46O3] 430.3447, found
430.3442.
4.1.15. (5E,7E)-(1S,2S,3S,20S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (7f)
This compound was obtained from 5c by the same procedure
as described for 6a : UV (EtOH) Vmax 274 nm, Vmin 231 nm; 1H
NMR (400 MHz, CDCl3) N 0.57 (3 H, s), 0.86 (3 H, d, J = 6.4
Hz), 1.22 (6 H, s), 1.24 (3 H, d, J = 7.3 Hz), 2.27 (1 H, br. d,
J = 14.1 Hz), 2.87 (1 H, dd, J = 12.5, 4.0 Hz), 3.06 (1 H, dd,
J = 14.0, 3.7 Hz), 3.98 (1 H, m), 4.20 (1 H, m), 4.91 (1 H, d,
J = 1.8 Hz), 5.12 (1 H, d, J = 1.8 Hz), 5.92 (1 H, d, J = 11.6
Hz), 6.66 (1 H, d, J = 11.9 Hz); MS 430 [M], 412 [M3H2O],
397 [M3H2O3Me] ; HRMS calcd. for [C28H46O3] 430.3447,
found 430.3453.
4.1.16. (5E,7E)-(1R,2R,3S,20S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (7g)
This compound was obtained from 5h by the same procedure
as described for 6a : UV (EtOH) Vmax 275 nm, Vmin 231 nm; 1H
NMR (400 MHz, CDCl3) N 0.57 (3 H, s), 0.86 (3 H, d, J = 6.7
Hz), 1.14 (3 H, d, J = 7.0 Hz), 1.22 (6 H, s), 2.13 (1 H, dd,
J = 13.7, 8.5 Hz), 2.85 (1 H, dd, J = 11.9, 4.0 Hz), 3.01 (1 H,
dd, J = 14.0, 4.6 Hz), 3.86 (1 H, dt, J = 4.9, 8.5 Hz). 4.29 (1 H,
d, J = 2.7 Hz), 4.92 (1 H, d, J = 1.2 Hz), 5.10 (1 H, d, J = 1.8 Hz),
5.88 (1 H, d, J = 11.6 Hz), 6.55 (1 H, d, J = 11.3 Hz); MS
430 [M], 412 [M3H2O], 397 [M3H2O3Me], 379
[M32H2O3Me] ; HRMS calcd. for [C28H46O3] 430.3447, found
430.3444.
4.1.17. (5E,7E)-(1R,2S,3S,20S)-2-Methyl-9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-triol (7h)
This compound was obtained from 5g by the same procedure
as described for 6a : UV (EtOH) Vmax 274 nm, Vmin 231 nm; 1H
NMR (400 MHz, CDCl3) N 0.56 (3 H, s), 0.86 (3 H, d, J = 6.4
Hz), 1.08 (3 H, d, J = 7.0 Hz), 1.21 (6 H, s), 2.53 (1 H, dd,
J = 14.3, 3.1 Hz), 2.60 (1 H, dd, J = 14.3, 5.8 Hz), 2.85 (1 H,
dd, J = 12.5, 4.3 Hz), 4.16 (2 H, m), 5.01 (1 H, d, J = 1.2 Hz),
5.15 (1 H, d, J = 1.2 Hz), 5.86 (1 H, d, J = 11.6 Hz), 6.60
(1 H, d, J = 11.3 Hz); MS 430 [M], 412 [M3H2O], 397
[M3H2O3Me], 379 [M32H2O3Me] ; HRMS calcd. for
[C28H46O3] 430.3447. found 430.3446.
4.2. Binding to VDR
Bovine thymus 1K,25-dihydroxyvitamin D3 receptor was ob-
tained from Yamasa Biochemical (Chiba, Japan) and dissolved
in 0.05 M phosphate bu¡er (pH 7.4) containing 0.3 M KCl and
5 mM dithiothreitol just before use. The receptor solution (500 Wl,
0.23 mg protein) was pre-incubated with 50 Wl of ethanol solution
of 1K,25-dihydroxyvitamin D3 or an analogue at various concen-
trations for 60 min at 25‡C. Then, the receptor mixture was left
to stand overnight with 0.1 nM [3H]-1K,25-dihydroxyvitamin D3
at 4‡C. The bound and free [3H]-1K,25-dihydroxyvitamin D3
were separated by treatment with dextran-coated charcoal for
30 min at 4‡C and centrifuged at 3000 rpm for 10 min. The
supernatant (500 Wl) was mixed with ACS-II (9.5 ml) (Amersham,
UK) and the radioactivity was counted. The relative potency of
the analogues was calculated from their concentration needed to
displace 50% of [3H]-1K,25-dihydroxyvitamin D3 from its recep-
tor compared with the activity of 1K,25-dihydroxyvitamin D3
(assigned a 100% value).
4.3. Binding to DBP
Serum from vitamin D-de¢cient Wistar male rats was diluted
(U70 000) with 3.5 mM barbiturate bu¡er (pH 8.6) containing
0.13 M NaCl and 0.1% (w/v) bovine serum albumin (BSA) and
used as a source of DBP. The diluted serum (1 ml) was incubated
with 0.1 nM [3H]-25-hydroxyvitamin D3 and 100 Wl of ethanol
solution of 1K,25-dihydroxyvitamin D3 or an analogue at various
concentrations for 60 min at 4‡C. Unbound [3H]-25-hydroxyvita-
min D3 was removed by treatment with dextran-coated charcoal
for 10 min at 4‡C followed by centrifugation at 3000 rpm for
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10 min. The radioactivity of the supernatant (1 ml) was mea-
sured. The relative potency of the analogues was calculated
from their concentration needed to displace 50% of [3H]-25-hy-
droxyvitamin D3 from its binding protein compared with the
activity of 1K,25-dihydroxyvitamin D3 (assigned a 100% value).
4.4. Cell surface antigen expression analysis
HL-60 cells were seeded at 105 cells/well in 24-well plates, and
incubated for 72 h with between 10311 M and 1037 M (or 1038
M) 1K,25-dihydroxyvitamin D3 or an analogue at 37‡C in a hu-
midi¢ed atmosphere of 5% carbon dioxide in air. The cells were
then washed with PBS and diluted with 50 Wl of Diluent solution
(PBS (minus Mg2 minus Ca2) containing 1% BSA and 1%
NaN3). Aliquots of cell suspension (50 Wl) were incubated with
5 Wl of the human monoclonal £uorescein isothiocyanate-conju-
gated CD11b antibody for 30 min at room temperature in the
dark. The cells were washed once with 1 ml of Diluent solution
and then ¢xed in 300 Wl of PBS containing 2% paraformaldehyde.
Fluorescence was read on a Becton Dickinson FACSan1 at an
excitation wavelength of 490 nm and emission wavelength of 520
nm. Results were recorded as the mean £uorescence index, which
is the product of the percent £uorescence and the mean £uores-
cence intensity, with 104 cells being counted per treatment. Re-
sults were expressed as percentage activity (at 50% of the dose-
response) in comparison with 1K,25-dihydroxyvitamin D3 (as-
signed a 100% value).
4.5. Molecular modeling
4.5.1. Conformational analysis
The A-ring conformations of the vitamin D analogues were
calculated using model compounds lacking the side chain at
C22 by MacroModel1 version 6.5 (Schroedinger) on a Silicon
Graphics O2 workstation. Conformational search was performed
with the Monte Carlo method of MacroModel1.
4.5.2. Docking studies
The coordinates of mutant human VDR complexed to 1 were
taken from the Brookhaven Protein Data Bank (PDB code
1DB1) and hydrogen atoms were added computationally at ap-
propriate positions. The following 32 amino acid residues in the
LBD, which are in the vicinity of 1, were used for the calculation:
Tyr-143, Asp-144, Tyr-147, Asp-149, Phe-150, Leu-227, Leu-230,
Leu-233, Val-234, Tyr-236, Ser-237, Ile-268, Ile-271, Met-272,
Arg-274, Ser-275, Ser-278, Trp-286, Cys-288, Tyr-293, Tyr-295,
Val-300, Ala-303, His-305, Leu-309, Leu-313, His-397, Tyr-401,
Leu-404, Leu-414, Val-418 and Phe-422. The residues were con-
strained with a force constant of 100.0 kJ. Structures of vitamin
D analogues bound to VDR were constructed by molecular dy-
namics (MD) simulation and molecular mechanics (MM) energy
minimization. The starting position of the ligand was determined
manually: the A-ring moiety of the ligand was superimposed
onto its crystallographic counterpart of 1 in the LBD. MD sim-
ulation was performed during 10 ps at 300 K. A hundred struc-
tures sampled from MD simulation were minimized by MM cal-
culation based upon the AMBER* force ¢eld. MD simulation
performed during 100 ps at 3000 K, with a force constant of
10 000 kJ, gave similar results. All calculations were performed
by MacroModel1 version 6.5 (Schroedinger) on a Silicon
Graphics O2 workstation.
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